{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.7","upperLimit":"73.2","value":"62.0"}]}],"title":"Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.5","upperLimit":"48.9","value":"36.6"}]}],"title":"Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.8","upperLimit":"44.5","value":"32.4"}]}],"title":"Day 100"}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"Defined as the percentage of participants demonstrating a CR, VGPR, or PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants began oral administration of ruxolitinib at 5 mg BID; if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID up to approximately 27 months. Participants did receive prednisone daily orally (PO) daily or methylprednisolone daily intravenously( IV) as per protocol.","id":"OG000","title":"Ruxolitinib in Combination With Corticosteroids"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Population included all participants enrolled in this study.","reportingStatus":"POSTED","timeFrame":"From baseline to days 14, 56, and 100","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}